Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CRIS

CRIS - Curis Inc Stock Price, Fair Value and News

6.92USD+0.05 (+0.73%)Market Closed

Market Summary

CRIS
USD6.92+0.05
Market Closed
0.73%

CRIS Stock Price

View Fullscreen

CRIS RSI Chart

CRIS Valuation

Market Cap

40.8M

Price/Earnings (Trailing)

-0.85

Price/Sales (Trailing)

4.16

Price/Free Cashflow

-1.03

CRIS Price/Sales (Trailing)

CRIS Profitability

Return on Equity

-504.44%

Return on Assets

-76.95%

Free Cashflow Yield

-96.76%

CRIS Fundamentals

CRIS Revenue

Revenue (TTM)

9.8M

Rev. Growth (Yr)

-9.19%

Rev. Growth (Qtr)

-22.63%

CRIS Earnings

Earnings (TTM)

-47.7M

Earnings Growth (Yr)

-2.74%

Earnings Growth (Qtr)

-1.4%

Breaking Down CRIS Revenue

Last 7 days

10.7%

Last 30 days

-19.4%

Last 90 days

-54.7%

Trailing 12 Months

695.4%

How does CRIS drawdown profile look like?

CRIS Financial Health

Current Ratio

4.08

CRIS Investor Care

Shares Dilution (1Y)

22.01%

Diluted EPS (TTM)

-8.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.8M000
202310.4M10.2M10.2M10.0M
202210.5M10.6M10.4M10.2M
202110.3M10.2M10.5M10.6M
202010.9M11.2M11.1M10.8M
20199.7M9.5M9.5M10.0M
201810.2M10.5M10.9M10.4M
20177.9M8.3M9.0M9.9M
20167.9M7.5M7.3M7.5M
201510.2M7.5M7.8M7.9M
201415.4M14.8M9.4M9.8M
20137.5M8.5M15.2M15.0M
201219.6M24.5M29.4M17.0M
201115.7M15.4M15.1M14.8M
2010011.1M13.5M16.0M
20090008.6M

Tracking the Latest Insider Buys and Sells of Curis Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 31, 2022
dentzer james e
sold
-9,498
3.07
-3,094
president & ceo
Jan 27, 2022
dentzer james e
sold
-7,651
3.18
-2,406
president & ceo
Jan 26, 2021
dentzer james e
sold
-32,758
10.5876
-3,094
president & ceo
Jan 25, 2021
dentzer james e
sold
-25,021
10.96
-2,283
president & ceo
Jan 24, 2020
dentzer james e
sold
-5,076
1.6407
-3,094
president & ceo
Jan 23, 2020
dentzer james e
sold
-6,181
1.6899
-3,658
president & ceo
Jan 24, 2019
dentzer james e
sold
-3,576
1.1561
-3,094
president & ceo
Jan 23, 2019
greenacre martyn d
sold
-19,474
1.0527
-18,500
-
Jan 23, 2019
kaitin kenneth i
sold
-15,587
1.0532
-14,800
-
Jan 23, 2019
dentzer james e
sold
-2,612
1.09
-2,397
president & ceo

1–10 of 14

Which funds bought or sold CRIS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 10, 2024
CWM, LLC
added
5,000
-
-
-%
Jun 17, 2024
TruNorth Capital Management, LLC
new
-
11.00
11.00
-%
May 17, 2024
VIMA LLC
sold off
-100
-38.00
-
-%
May 17, 2024
Artal Group S.A.
sold off
-100
-1,339,000
-
-%
May 16, 2024
COMERICA BANK
unchanged
-
-188
1,087
-%
May 15, 2024
MAVERICK CAPITAL LTD
unchanged
-
-1,094,670
6,329,310
0.12%
May 15, 2024
MORGAN STANLEY
reduced
-0.56
-1,734
9,664
-%
May 15, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.
reduced
-50.00
-4,157,120
3,088,710
0.34%
May 15, 2024
Royal Bank of Canada
added
155
1,000
4,000
-%
May 15, 2024
STATE STREET CORP
unchanged
-
-39,572
228,803
-%

1–10 of 46

Are Funds Buying or Selling CRIS?

Are funds buying CRIS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRIS
No. of Funds

Unveiling Curis Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 15, 2024
kingdon capital management, l.l.c.
5.9%
345,730
SC 13G
Feb 14, 2024
maverick capital ltd
9.9%
582,273
SC 13G/A
Feb 12, 2024
m28 capital management lp
7.2%
421,951
SC 13G
Feb 14, 2023
maverick capital ltd
5.8%
5,555,598
SC 13G/A
Jan 20, 2023
state street corp
0.26%
255,009
SC 13G/A
Jul 08, 2022
blackrock inc.
2.6%
2,359,787
SC 13G
Feb 14, 2022
point72 asset management, l.p.
1.6%
1,442,543
SC 13G/A
Feb 14, 2022
maverick capital ltd
8.5%
7,790,478
SC 13G
Feb 11, 2022
state street corp
8.51%
7,799,328
SC 13G
Feb 04, 2022
blackrock inc.
6.9%
6,281,041
SC 13G

Recent SEC filings of Curis Inc

View All Filings
Date Filed Form Type Document
Jun 14, 2024
S-8
Employee Benefits Plan
May 23, 2024
8-K
Current Report
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading

Peers (Alternatives to Curis Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
47.1B
6.8B
-17.23% -2.46%
-7.89
6.87
-64.45% -224.75%
33.0B
2.0B
67.01% 29.40%
-99.52
16.5
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.9B
2.5B
0.02% -1.58%
77.53
6.44
13.74% 186.89%
14.0B
3.8B
4.74% -0.56%
18.77
3.71
8.58% 129.81%
MID-CAP
5.0B
107.9M
-2.22% 48.86%
-9.2
48.09
54.84% -28.31%
4.7B
524.1M
-9.01% -54.24%
-11.31
9.01
394.93% 39.61%
4.0B
251.0M
18.93% 13.89%
-13.54
15.99
73.58% -86.73%
3.5B
240.7M
14.65% -16.72%
-7.42
12.77
-1.03% -213.92%
2.9B
813.8M
17.43% -31.75%
-1.7K
3.58
56.43% 98.83%
1.8B
996.6M
-22.65% 38.54%
-4.56
1.82
-26.66% 65.49%
SMALL-CAP
1.9B
411.3M
4.82% 27.42%
29.58
4.68
60.38% -34.49%
570.7M
881.7K
6.14% 580.25%
-16.91
481.06
-77.61% 33.36%
286.3M
4.2M
13.80% 73.74%
-2.29
68.83
-66.30% 48.24%
18.6M
2.1M
-12.55% 263.94%
-0.8
7.61
-13.45% 69.54%

Curis Inc News

Latest updates
StockTitan47 hours ago
Marketscreener.com08 Jul 202411:31 am

Curis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-22.6%2,0862,6962,8332,1972,2972,8872,8252,3932,0573,1353,0392,2862,1893,0242,7422,3602,7093,2872,8562,0941,767
Costs and Expenses-2.3%14,55514,89515,20114,33513,92413,10715,43117,45417,19015,70213,08712,93610,9899,2997,4537,79011,19110,6218,1798,2357,325
  S&GA Expenses0.3%4,8914,8774,7614,2494,7604,3304,5565,0895,6734,7734,3344,0674,1233,5392,6132,3863,5932,9992,8872,5263,143
Interest Expenses-100.0%-1827537636611,0191,0021,0171,0741,0801,0521,1121,193-2,443--1,062---791
Net Income-1.4%-11,876-11,712-12,181-11,961-11,559-11,329-13,294-15,940-16,109-13,620-11,051-10,838-9,927-7,517-5,974-6,708-9,709-8,609-6,436-7,213-9,884
Net Income Margin-2.8%-4.86*-4.73*-4.60*-4.72*-5.01*-5.58*-5.66*-5.34*-4.91*-4.27*-3.73*-3.34*---------
Free Cashflow-29.3%-13,232-10,234-8,181-7,868-12,199-12,268-13,174-12,485-16,826-8,171-9,610-6,659---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-19.7%62.0077.0090.0084.0095.0010912312914116217218119120446.0045.0027.0035.0042.0048.0055.00
  Current Assets-24.4%46.0061.0073.0068.0078.0092.0010611312612213515716217328.0027.0017.0025.0033.0038.0045.00
    Cash Equivalents12.3%30.0027.0024.0020.0032.0020.0030.0035.0019.0041.0054.0076.0011213024.0025.0014.0016.0021.0027.0043.00
  Net PPE-14.7%0.000.000.001.001.001.001.001.000.001.001.001.001.001.001.001.000.000.000.000.000.00
  Goodwill0%9.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.00
Liabilities-8.8%53.0058.0060.0058.0058.0062.0067.0067.0065.0072.0069.0069.0069.0074.0074.0075.0067.0069.0068.0069.0069.00
  Current Liabilities-16.4%11.0014.0014.0010.008.0010.0014.0012.0010.0013.009.008.007.0010.009.009.006.007.005.004.005.00
  Long Term Debt--------------0.001.000.00-----
    LT Debt, Current-------------1.001.000.000.00-----
    LT Debt, Non Current--------------0.001.000.00-----
Shareholder's Equity-51.9%9.0020.0030.0026.0037.0047.0056.0062.0076.0091.00103112122131-------
  Retained Earnings-1.0%-1,208-1,196-1,200-1,172-1,160-1,149-1,137-1,124-1,100-1,092-1,078-1,067-1,056-1,046-1,000-1,000-1,000-1,016-1,008-1,000-994
  Additional Paid-In Capital0.1%1,2171,2161,2141,1981,1961,1961,1931,1861,1841,1821,1811,1791,1781,1771,0101,003986983982981981
Shares Outstanding0%6.006.006.005.005.005.005.005.005.005.005.005.00---------
Float----82.00---90.00---737---54.00---51.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-29.3%-13,232-10,234-8,133-7,868-12,199-12,268-13,122-12,132-16,815-8,171-9,610-6,659-13,179-5,715-5,877-5,131-9,016-5,599-6,704-6,669-7,233
  Share Based Compensation0.7%1,5591,5481,6331,4241,3951,7441,3241,9661,7181,4411,4641,2751,099865623585625692684631651
Cashflow From Investing30.3%18,91314,517180-3,15426,2433,4634,30328,340-3,083-3,523-11,530-28,771-4,071-53,469-162-2584,8411,5491,453-8,058600
Cashflow From Financing-13.6%-2,406-2,11812,556-852-2,006-1,3884,662-759-1,648-1,312-956-575-1,329165,2395,82016,4781,277-1,061-611-82025,763
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CRIS Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenues, net$ 2,086$ 2,297
Operating expenses:  
Cost of royalties4724
Research and development9,6179,140
General and administrative4,8914,760
Total operating expenses14,55513,924
Loss from operations(12,469)(11,627)
Other income:  
Interest income515652
Income (expense) related to the sale of future royalties78(584)
Total other income59368
Net loss$ (11,876)$ (11,559)
Net loss per common share (basic ) (in dollars per share)$ (2.05)$ (2.39)
Net loss per common share (diluted) (in dollars per share)$ (2.05)$ (2.39)
Weighted average common shares (basic) (in shares)5,783,5854,830,763
Weighted average common shares (diluted) (in shares)5,783,5854,830,763
Net loss$ (11,876)$ (11,559)
Other comprehensive income:  
Unrealized gain on marketable securities109195
Comprehensive loss$ (11,767)$ (11,364)

CRIS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 29,956$ 26,681
Short-term investments10,76429,653
Accounts receivable2,1542,794
Prepaid expenses and other current assets3,1921,780
Total current assets46,06660,908
Property and equipment, net370434
Restricted cash, long-term544544
Operating lease right-of-use asset2,7043,056
Other assets3,3583,358
Goodwill8,9828,982
Total assets62,02477,282
Current liabilities:  
Accounts payable3,6283,172
Accrued liabilities6,3269,040
Current portion of operating lease liability1,3491,305
Total current liabilities11,30313,517
Long-term operating lease liability1,1371,489
Liability related to the sale of future royalties, net40,12242,606
Total liabilities52,56257,612
Stockholders’ equity:  
Preferred stock, $0.01 par value—5,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.01 par value—22,781,250 shares authorized, 5,894,085 shares issued and outstanding at March 31, 2024 and December 31, 20235959
Additional paid-in capital1,217,3511,215,792
Accumulated deficit(1,208,286)(1,196,410)
Accumulated other comprehensive gain338229
Total stockholders’ equity9,46219,670
Total liabilities and stockholders’ equity$ 62,024$ 77,282
Common stock issued (in shares)5,894,0855,894,085
Common stock outstanding (in shares)5,894,0855,894,085
Common stock authorized (in shares)22,781,25022,781,250
CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEcuris.com
 INDUSTRYBiotechnology
 EMPLOYEES51

Curis Inc Frequently Asked Questions


What is the ticker symbol for Curis Inc? What does CRIS stand for in stocks?

CRIS is the stock ticker symbol of Curis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Curis Inc (CRIS)?

As of Thu Jul 11 2024, market cap of Curis Inc is 40.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRIS stock?

You can check CRIS's fair value in chart for subscribers.

What is the fair value of CRIS stock?

You can check CRIS's fair value in chart for subscribers. The fair value of Curis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Curis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRIS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Curis Inc a good stock to buy?

The fair value guage provides a quick view whether CRIS is over valued or under valued. Whether Curis Inc is cheap or expensive depends on the assumptions which impact Curis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRIS.

What is Curis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 11 2024, CRIS's PE ratio (Price to Earnings) is -0.85 and Price to Sales (PS) ratio is 4.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRIS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Curis Inc's stock?

In the past 10 years, Curis Inc has provided -0.03 (multiply by 100 for percentage) rate of return.